Compare AQMS & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AQMS | BCTX |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 18.5M |
| IPO Year | 2015 | N/A |
| Metric | AQMS | BCTX |
|---|---|---|
| Price | $8.05 | $10.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $12.00 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 260.6K | 43.8K |
| Earning Date | 11-12-2025 | 12-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $550.00 | $380.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.37 | $6.00 |
| 52 Week High | $39.40 | $190.50 |
| Indicator | AQMS | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.14 | 50.80 |
| Support Level | $7.25 | $9.25 |
| Resistance Level | $8.28 | $10.52 |
| Average True Range (ATR) | 0.79 | 0.80 |
| MACD | 0.16 | 0.19 |
| Stochastic Oscillator | 84.62 | 79.88 |
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.